These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 20660056

  • 21. High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease.
    Takeshita A, Inoshita N, Taguchi M, Okuda C, Fukuhara N, Oyama K, Ohashi K, Sano T, Takeuchi Y, Yamada S.
    Eur J Endocrinol; 2009 Oct; 161(4):553-9. PubMed ID: 19589911
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.
    Adachi J, Mishima K, Wakiya K, Suzuki T, Fukuoka K, Yanagisawa T, Matsutani M, Sasaki A, Nishikawa R.
    J Neurooncol; 2012 Mar; 107(1):147-53. PubMed ID: 21968944
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.
    Micko ASG, Wöhrer A, Höftberger R, Vila G, Marosi C, Knosp E, Wolfsberger S.
    Pituitary; 2017 Dec; 20(6):643-653. PubMed ID: 28900805
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
    Ceccato F, Lombardi G, Manara R, Emanuelli E, Denaro L, Milanese L, Gardiman MP, Bertorelle R, Scanarini M, D'Avella D, Occhi G, Boscaro M, Zagonel V, Scaroni C.
    J Neurooncol; 2015 Mar; 122(1):189-96. PubMed ID: 25555563
    [Abstract] [Full Text] [Related]

  • 32. Expression profiling of O(6) methylguanine-DNA-methyl transferase in prolactinomas: a correlative study of promoter methylation and pathological features in 136 cases.
    Jiang XB, Hu B, He DS, Mao ZG, Wang X, Song BB, Zhu YH, Wang HJ.
    BMC Cancer; 2015 Sep 23; 15():644. PubMed ID: 26400193
    [Abstract] [Full Text] [Related]

  • 33. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
    Schraml P, von Teichman A, Mihic-Probst D, Simcock M, Ochsenbein A, Dummer R, Michielin O, Seifert B, Schläppi M, Moch H, von Moos R.
    Oncol Rep; 2012 Aug 23; 28(2):654-8. PubMed ID: 22614944
    [Abstract] [Full Text] [Related]

  • 34. Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
    Sartore-Bianchi A, Pietrantonio F, Amatu A, Milione M, Cassingena A, Ghezzi S, Caporale M, Berenato R, Falcomatà C, Pellegrinelli A, Bardelli A, Nichelatti M, Tosi F, De Braud F, Di Nicolantonio F, Barault L, Siena S.
    Eur J Cancer; 2017 Jan 23; 71():43-50. PubMed ID: 27997874
    [Abstract] [Full Text] [Related]

  • 35. Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome.
    Salehi F, Scheithauer BW, Moyes VJ, Drake WM, Syro LV, Manoranjan B, Sharma S, Horvath E, Kovacs K.
    Endocr Pathol; 2010 Dec 23; 21(4):227-9. PubMed ID: 21061089
    [Abstract] [Full Text] [Related]

  • 36. MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern.
    Zuhur SS, Tanik C, Karaman Ö, Velet S, Çil E, Öztürk FY, Özkayalar H, Müslüman AM, Altuntaş Y.
    Endocrine; 2011 Oct 23; 40(2):222-7. PubMed ID: 21792693
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents.
    Walter T, van Brakel B, Vercherat C, Hervieu V, Forestier J, Chayvialle JA, Molin Y, Lombard-Bohas C, Joly MO, Scoazec JY.
    Br J Cancer; 2015 Feb 03; 112(3):523-31. PubMed ID: 25584486
    [Abstract] [Full Text] [Related]

  • 39. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK.
    Pediatr Blood Cancer; 2007 Apr 03; 48(4):403-7. PubMed ID: 16609952
    [Abstract] [Full Text] [Related]

  • 40. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
    Jha P, Suri V, Jain A, Sharma MC, Pathak P, Jha P, Srivastava A, Suri A, Gupta D, Chosdol K, Chattopadhyay P, Sarkar C.
    Neurosurgery; 2010 Dec 03; 67(6):1681-91. PubMed ID: 21107199
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.